Cite
HARVARD Citation
Day, T. et al. (2021). Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 9 (4), pp. 373-386. [Online].